Key Drivers
- Strong liquidity
- Large cash burn
- High leverage
AIAI Summary
Biohaven has transformed into a multi‑program, event‑driven biotech with meaningful upside if immunology and at least one neurology/metabolic 2026 readout succeed, but acute cash burn and high leverage make near‑term financing the critical binary risk—monitor 2026 trial data, cash runway, and partnership/financing moves as decisive catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Large cash burn
- •High leverage
BHVN has solid near-term liquidity and tangible assets but zero revenue, massive R&D-driven cash burn and deep operating losses with high leverage versus equity, creating acute solvency and valuation risk.
Price Behavior
Key Price Behavior Insights:
- •Clear downtrend
- •Below moving average
- •Support tested
Over the last month the stock dropped about 20.5% from $11.23 to $8.93 and sits well below its last-month 21-period moving average (~$10.42), signaling a short-term downtrend unless it reclaims the $11.8–$11.9 resistance band.
~20.5% decline over the last month from $11.23 to $8.93 indicating strong short-term bearish momentum
Sentiment & News
Key News Insights:
- •Rapid IgG suppression
- •Epilepsy readthrough
- •Obesity Phase‑2
Biohaven is pushing three prioritized late‑stage programs—IgG MoDE/TRAP showed rapid patient antibody suppression, Kv7/epilepsy momentum lifted by peer Phase 3 success, and taldefgrobep alfa finished Phase 2 enrollment with topline due H2 2026—creating multiple near‑term clinical catalysts.
Positive near‑term catalysts should lift valuation if readouts confirm efficacy, but results will also heighten share volatility around trial milestones
Similar Companies in Healthcare
Other companies in the same sector with AI ratings